TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in adult patients with relapsing forms of multiple sclerosis (RMS), presented at the 2023 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum. Links to each of the presentations are included below.
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are excited to share additional exploratory analyses from the ULTIMATE I & II Phase 3 trials at the ACTRIMS conference this week. We believe these data further support the unique attributes of BRIUMVI which is now commercially available, and we look forward to continuing to share additional analyses throughout the year.”
PRESENTATIONS
Poster Presentation: Early, Transient Shift in Hematologic Parameters Observed with Ublituximab in the ULTIMATE I and II Phase 3 Studies
Lead Author: Peiqing Qian, MD, Swedish Neuroscience Institute, Seattle, WA
Poster Presentation: Onset and Maintenance of No Evidence of Disease Activity with Ublituximab: Analyses of the Phase 3 ULTIMATE I and II Studies in Participants with Relapsing Multiple Sclerosis
Lead Author: Enrique Alvarez, MD, University of Colorado, Aurora, CO
The above presentations are also available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.
https://finance.yahoo.com/news/tg-therapeutics-announces-presentation-data-120000592.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.